September 24, 2026

To

BSE Limited
Corporate Relationship Department
25th Floor, P J Towers
Dalal Street, Fort,
Mumbai – 400 001.
BSE Scrip Code: 524743

National Stock Exchange of India Ltd.
Exchange Plaza, 5tll floor
Plot No. C/ 1, G Block,
Bandra-Kurla Complex Bandra (E),
Mumbai - 400 051.
NSE Symbol: FISCHER

Dear Sir/ Madam,

Sub: Outcome of Board Meeting held on 24th September, 2026

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors have inter-alia approved and taken on record the following at its meeting held today (24/09/2026):

1. **Rights Issue by Material Unlisted Subsidiary Companies**

(i) **Time Medical International Ventures (India) Private Limited**, a Wholly Owned Subsidiary of the Company and a material subsidiary under Regulation 24(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has issued 15,603 equity shares at an issue price of ₹ 7,370.25 per equity share by way of a rights issue.

(ii) **Flynncare Health Innovations Private Limited**, the Wholly Owned Subsidiary of the Company and also a material subsidiary under Regulation 24(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has issued 1,507 equity shares at an issue price of ₹82,943.48 per equity share by way of a rights issue.

(iii) **FMV Global Innovation Pte. Ltd.**, the Wholly Owned Subsidiary of the Company and also a material subsidiary under Regulation 24(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has issued 53 equity shares at an issue price of ₹48,83,552.64 per equity share by way of a rights issue.

2. **Investment in Equity shares of wholly owned Material Subsidiaries of the Company**

The Board of Directors considered and approved the proposal for investment by the Company in the rights issues proposed to be undertaken by its wholly owned subsidiary companies, namely,

(a) Time Medical International Ventures (India) Private Limited,
(b) FlynnCare Health Innovations Private Limited and
(c) FMV Global Innovation Pte. Ltd.,

by subscribing to the equity shares offered by the respective entities pursuant to their respective rights issues, subject to the terms and conditions and applicable laws.

The details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 are given in **Annexure**.

The Board Meeting commenced at 02:15 PM (IST) and concluded at 4:10 PM (IST)

Please take on record.

Thanking You,
Yours Truly,

For **FISCHER MEDICAL VENTURES LIMITED**

BALAJI GANDLA Digitally signed by BALAJI GANDLA
Date: 2026.09.24 17:50:23 +05'30'

Fischer Medical Ventures Limited

BALAJI GANDLA
COMPANY SECRETARY AND COMPLIANCE OFFICER

ANNEXURE I)

Sr. no.	Particulars	Details
1	Name of the target entity, details in brief such as size, turnover etc.	**Time Medical International Ventures (India) Private Limited** Turnover: 5,500.50 lakhs for FY 2025-26
2	Whether the acquisition would fall within related party transaction(s)and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length".	Time Medical International Ventures (India) Private Limited is the wholly owned material subsidiary of the Company. Accordingly, Time Medical International Ventures (India) Private Limited is a related party. The transaction is done at Arm's Length and supported by a valuation report issued by a Registered Valuer.
3	Industry to which the entity acquired belongs	Healthcare
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Not Applicable.
5	Brief details of any governmental or regulatory approvals required for the acquisition.	Not Applicable.
6	Indicative time period for completion of the acquisition.	Not Applicable.
7	Nature of consideration - whether cash consideration or share swap and details of the same.	Cash
8	Cost of acquisition or ~~the price at which the shares are acquired~~.	INR 11,50,00,000
9	Percentage of shareholding/ control acquired and/ or number of shares acquired.	100%

FISCHER MEDICAL VENTURES LIMITED
(Formerly known as Fischer Chemic Limited)
Registered Office Address: Survey No. 480/2 AP Medtech Zone,
Nadupura Village, Pedagantyadu Mandal, Visakhapatnam, 530032
CIN: L86900AP1993PLC118162
Email: cs@fischermv.com | Website: www.fischermv.com | Contact 9080966548

10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief).	Time Medical International Ventures (India) Private Limited ("TMIV") is engaged in the medical diagnostic imaging industry, with a focus on developing and providing advanced and affordable medical imaging solutions. The company has capabilities in the development and manufacture of medical imaging systems, including Magnetic Resonance Imaging (MRI) systems, and operates a manufacturing facility at the Andhra Pradesh MedTech Zone (AMTZ), Visakhapatnam. TMIV has also developed cost-effective service solutions for the medical imaging sector. Date and Country of Incorporation: 10-01-2019, India Turnover for FY 2025-26: 5,500.05 lakhs Turnover for FY 2024-25: 8,273.58 lakhs Turnover for FY 2023-24: 2,162.34 lakhs

II)

Sr. no.	Particulars	Details
1	Name of the target entity, details in brief such as size, turnover etc.	**Flynncare Health Innovations Private Limited** Turnover: 8,629.26 lakhs
2	Whether the acquisition would fall within related party transaction(s)and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length".	Flynncare Health Innovations Private Limited is the wholly owned material subsidiary of the Company. Accordingly, Flynncare Health Innovations Private Limited is a related party. The transaction is done at Arm's Length and supported by a valuation report issued by a Registered Valuer.
3	Industry to which the entity acquired belongs	Healthcare
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Not Applicable.
5	Brief details of any governmental or regulatory approvals required for the acquisition.	Not Applicable.

6	Indicative time period for completion of the acquisition.	Not Applicable.
7	Nature of consideration - whether cash consideration or share swap and details of the same.	Cash
8	Cost of acquisition or ~~the price at which the shares are acquired.~~	INR 12,50,00,000
9	Percentage of shareholding/ control acquired and/ or number of shares acquired.	100%
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief).	FlynnCare Health Innovations Private Limited ("FlynnCare") is engaged in the digital healthcare space and leverages digital health technologies to provide end-to-end healthcare solutions. Its business includes a Digital Hospital platform, Community Care solutions, and integrated screening and diagnostic solutions, with a focus on improving connectivity between patients and healthcare providers through technology-enabled and data-driven solutions. Date and Country of Incorporation: 29-07-2024, India Turnover for FY 2025-26: 8,629.26 Lakhs Turnover for FY 2024-25: 2,742.46 Lakhs

III)

Sr. no.	**Particulars**	**Details**
1	Name of the target entity, details in brief such as size, turnover etc.	**FMV Global Innovations Pte Ltd** Turnover: Not applicable since the Company was incorporated in FY 2024-2025
2	Whether the acquisition would fall within related party transaction(s)and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length".	FMV Global Innovations Pte Ltd is the wholly owned material subsidiary of the Company. Accordingly, FMV Global Innovations Pte Ltd is a related party. The transaction is done at Arm's Length and supported by a valuation report issued by a Registered Valuer.
3	Industry to which the entity acquired belongs	Healthcare

4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Not Applicable.
5	Brief details of any governmental or regulatory approvals required for the acquisition.	Not Applicable.
6	Indicative time period for completion of the acquisition.	Not Applicable.
7	Nature of consideration - whether cash consideration or share swap and details of the same.	Cash
8	Cost of acquisition or the price at which the shares are acquired.	INR 26,00,00,000
9	Percentage of shareholding/ control acquired and/ or number of shares acquired**.**	100%
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief).	FMV Global Innovation Pte. Ltd. is a Singapore-incorporated company engaged in the wholesale, marketing and sale of medical, professional, scientific and precision equipment, including medical devices and diagnostic products. The company forms part of the Group's international medical technology business and supports the Group's activities in the global medical device and diagnostics market. Date and Country of Incorporation: 01-07-2024 Turnover for FY 2025-26: S$ 22,808,941 Turnover for FY 2024-25: Nil